On the afternoon of October 19, Mr. Chen Yaoshui, deputy director of Shanghai Office for Promoting the Construction of Science and Technology Innovation Center("Shanghai OPCSTIC”), and his party visited Mabwell Bioscience("Company") to do field research. Accompanied by Dr. Liu Datao, co-founder and CEO of the Company, they visited Mabwell Bioscience antibody drug innovation and research Center, listened to the report on the development of the Company, and had a discussion with relevant leaders of the Company.

Deputy director Mr. Chen Yaoshui had an in-depth understanding of the Company's achievements and practical difficulties encountered in the development process, had a detailed understanding of the five world-leading innovation discovery platforms and advantages of Mabwell Bioscience, and fully affirmed the rapid development, excellent talent team, rich and diversed product pipelines and efficient project promotion ability of Mabwell Bioscience. 

Deputy director Chen pointed out that rapid research and rapid listing, and two F's (First in Class, Fast follow-on) are the expectations for the development of Mabwell Bioscience. Shanghai OPCSTIC will actively support enterprises to strengthen the construction of sustainable innovation capacity, help enterprises overcome difficulties in various aspects in the process of project promotion and development, and assist enterprises to attract high-end talents through targeted policies, help promote the rapid and pragmatic development of Shanghai biopharmaceutical industry.

Dr. Liu Datao expressed his gratitude to the leaders of Shanghai OPCSTIC for their high expectations and policy support, which is the booster for the rapid development of innovative company like us. This year, Mabwell Bioscience has two domestic initiatives - China's first drug candidate that has been approved to clinical study among its domestic counterparts using the same target. We will continue to innovate actively, based on our latest achievements in China, with a view to achieving innovation globally and be the best innovator globally in the near future, and are committed to providing global patients with more effective and accessible innovative biologics.

Relevant officers of Shanghai OPCSTIC science platform division, talent service division and relevant executives of Mabwell Bioscience participated in this research.